PETER YAMAMOTO: Open Payments
NPI 1386796589 · WAIANAE, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,575 in 41 payments from 11 companies in 2025. Trend: 2023 $2,373 · 2024 $2,384 · 2025 $1,575
Food & beverage: $1,575
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 12 | $421 |
| Janssen Pharmaceuticals, Inc | 11 | $323 |
| Teva Pharmaceuticals USA, Inc. | 5 | $224 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $145 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $94 |
| ABBVIE INC. | 3 | $81 |
| Neurocrine BioSciences, Inc. | 1 | $72 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
Products named: INVEGA SUSTENNA, ARISTADA, UZEDY, CAPLYTA, ABILIFY MAINTENA, LYBALVI, VRAYLAR, INGREZZA.
Industry payments across HI — which companies pay providers there.
